Table 5.
Response rates and survival after MT-R, MT-R followed by EA, and by pre-treatment ADCmin values
| Total | Complete response |
Partial response |
Overall response |
Median OS |
Median PFS |
||||
|---|---|---|---|---|---|---|---|---|---|
| No. | No. | % | No. | % | No. | % | Months | Months | |
| MT-R | 31 | 16 | 52 | 2 | 6 | 18 | 58 | 66 | 24 |
| MT-R → EA | 14 | NR | NR | ||||||
| ADCmin (× 10−6mm2/s) | |||||||||
| ≥384 | 15 | 10 | 67 | 0 | 0 | 10 | 67 | NR | NR |
| <384 | 8 | 2 | 25 | 1 | 13 | 3 | 38 | 12 | 2 |
Abbreviations: OS, overall survival; PFS, progression-free survival; MT-R, all patients receiving rituximab, methotrexate and temozolomide; MT-R → EA, patients receiving MT-R followed by high-dose etoposide and cytarabine consolidation; NR, not reached; ADCmin, minimum apparent diffusion coefficient